Cryoport opens new global supply chain center near Paris

LOUVRES, FRANCE - Cryoport, Inc. (NASDAQ:CYRX), a $475 million market cap company trading near its InvestingPro Fair Value, launched a new 55,000-square-foot facility near Paris Charles de Gaulle Airport on Wednesday, expanding its temperature-controlled supply chain network for life sciences.

The Louvres facility is the third campus in Cryoport Systems’ Global Supply Chain Center network and is immediately operational for logistics support in biopharma, including cell and gene therapies, biologics, animal health, and reproductive medicine. The expansion comes as the company maintains a strong financial health score of 2.7 out of 3.0 on InvestingPro, with liquid assets exceeding short-term obligations.

According to a company press release, the facility will initially focus on logistics operations with 24-hour worldwide dispatch capabilities. In coming months, it will add BioServices, biostorage, QP drug management, and Importer of Record services to support both clinical and commercial cell and gene therapy programs.

"Our new facility in Louvres strengthens Cryoport Systems’ Global Supply Chain Center Network significantly and provides us with increased ability to serve our clients in the European and global markets," said Jerrell Shelton, CEO of Cryoport.

The Paris facility was partially funded by a grant from the Île-de-France region to promote economic growth in the area. An official grand opening celebration is scheduled for November 20, 2025. This strategic expansion follows impressive growth, with revenue increasing 25% over the last twelve months. Get deeper insights into Cryoport’s growth potential with a comprehensive Pro Research Report, available exclusively on InvestingPro, along with 8 additional key ProTips for informed investment decisions.

The new center is designed to provide end-to-end temperature-controlled supply chain solutions under one roof, addressing challenges in the advanced therapies market while offering global accessibility for biopharma and other temperature-sensitive commodities.

Cryoport’s integrated supply chain platform includes the Cryoportal Logistics Management Platform, temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems.

In other recent news, CryoPort has reported impressive second-quarter results, with revenue growth across multiple segments. The company experienced a 33% increase in commercial cell and gene therapies, a 28% rise in its BioStorage business, and a 21% growth in Life Sciences Services. Following these strong results, KeyBanc upgraded CryoPort’s stock rating to Overweight, setting a price target of $15.00. BTIG also raised its price target for CryoPort to $15.00 from $10.00, maintaining a Buy rating due to an improving industry outlook.

Meanwhile, Leerink Partners upgraded CryoPort to Outperform from Market Perform, citing the company’s dominant market position and growth potential, with a new price target of $16.00. Jefferies increased its price target to $8.00, noting the company’s impressive second-quarter performance, which exceeded consensus expectations by 9%. KeyBanc also highlighted the positive regulatory environment for cell and gene therapy companies, which benefits CryoPort. These recent developments reflect CryoPort’s strong market position and growth prospects in the cell and gene therapy sector.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.